Zoledronic acid linked to early increase in sclerostin levels
(HealthDay)—Women with postmenopausal osteoporosis treated with zoledronic acid show an early increase in serum levels of the negative regulator of bone formation, sclerostin, that return close to baseline ...
Medications
Apr 29, 2013 |
not rated yet |
0
Common osteoporosis drug slows formation of new bone
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of ...
Medications
Apr 17, 2013 |
5 / 5 (1) |
0
Zoledronic acid does not prevent bone metastases in high-risk PCa patients
The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary ...
Cancer
Mar 19, 2013 |
not rated yet |
0
Once-yearly zoledronic acid benefits men with osteoporosis
(HealthDay)—For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published ...
Diseases, Conditions, Syndromes
Nov 02, 2012 |
not rated yet |
0
Denosumab superior to zoledronic acid for breast cancer patients with bone metastases
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, ...
Cancer
Aug 14, 2012 |
not rated yet |
0
|
Immediate bisphosphonate use with endocrine therapy increased survival in postmenopausal early breast cancer
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according ...
Cancer
Dec 07, 2011 |
not rated yet |
0
Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian ...
Cancer
Dec 07, 2011 |
not rated yet |
0
Drug prevents bone loss side effects of breast cancer medication
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Societ ...
Cancer
Oct 10, 2011 |
not rated yet |
0
|
Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women
A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer ...
Cancer
Sep 25, 2011 |
not rated yet |
0
Yearly zoledronic acid at lower-than-standard doses increases bone density
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic ...
Diseases, Conditions, Syndromes
Jun 06, 2011 |
not rated yet |
0
